Related Experiment Video
Updated: May 16, 2026
05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
Retatrutide And Lipid And Metabolite Profiles In Participants With Obesity With Or Without Type 2 Diabetes
Mackenzie J Pearson1, Jill A Willency1, Yanzhu Lin1
1Eli Lilly and Company, Indianapolis, IN, USA.
The Journal of Clinical Endocrinology and Metabolism
|May 14, 2026
Summary
Retatrutide treatment altered key metabolites related to fatty acid oxidation and insulin resistance in individuals with obesity and type 2 diabetes. These metabolic shifts suggest improved metabolic health and reduced cardiovascular risk.
Area of Science:
- Metabolomics and lipidomics
- Pharmacology and drug development
- Endocrinology and metabolic diseases
Background:
- Phase 2 trials demonstrated retatrutide's efficacy in reducing body weight, HbA1c, and improving lipid profiles in individuals with obesity, with or without type 2 diabetes (T2D).
- Understanding the underlying metabolic changes associated with retatrutide treatment is crucial for elucidating its mechanism of action and clinical benefits.
Purpose of the Study:
- To comprehensively assess plasma metabolome and lipidome alterations in response to retatrutide therapy.
- To explore the relationship between metabolic changes and treatment outcomes, including weight reduction and insulin resistance.
Main Methods:
- Plasma samples from two randomized, placebo-controlled phase 2 trials involving participants with obesity (with and without T2D) were analyzed using metabolomics and lipidomics.
- Participants received varying doses of retatrutide or placebo for 36-48 weeks.
- Post-hoc exploratory analysis utilized multiplicity correction to identify significant changes in metabolite and lipid levels.
Main Results:
- Higher doses of retatrutide induced significant changes in metabolites associated with fatty acid oxidation, including 3-hydroxybutyrate and acylcarnitines.
- Mediation analyses indicated that these metabolic changes accounted for a substantial portion of weight reduction, particularly in participants without T2D.
- Retatrutide also modulated metabolites linked to insulin resistance, such as branched-chain amino acids and triglycerides, with sustained effects observed throughout the study.
Conclusions:
- Retatrutide treatment is associated with favorable alterations in metabolic pathways, specifically those involved in fatty acid oxidation and insulin resistance.
- These observed metabolic changes are directionally consistent with improved metabolic health and a potential reduction in cardiovascular risk.
Related Concept Videos
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
01:24Obesity
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
01:21Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...